bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for fourth-quarter and full-year 2014.
Asia
Europe, Middle East, Africa
North America
bioMérieux’s business review for the year ended December 31, 2014
22 January, 2015
bioMérieux and Astute Medical agreement to develop and market NEPHROCHECK® Test for VIDAS®
22 January, 2015
bioMérieux and Astute Medical sign a global agreement to develop and market NEPHROCHECK® Test for VIDAS®, an assay to assess the risk of developing acute kidney injury
Strategic alliance between bioMérieux and COPAN to automate clinical microbiology laboratories and enhance their operational efficiency
09 January, 2015
bioMérieux distributes COPAN’s WASP® and WASPLab™ automated systems and speeds up deployment of its “FMLA® - Lab Efficiency” vision.
bioMérieux and Illumina Enter Agreement to Co-Develop a Next-Generation Sequencing Solution for Epidemiological Monitoring of Bacterial Infections
10 December, 2014
bioMérieux, a world leader in the field of in vitro diagnostics, and Illumina, a world leader in genomics, announced they have signed an exclusive agreement to launch a next-generation sequencing (NGS) epidemiology solution for service labs.
bioMérieux Launches 3P™ Culture Media Range for Cleanrooms and Isolators
10 November, 2014
bioMérieux Industry, a bioMérieux unit dedicated to industrial application diagnostics, announces the launch of 3PTM, the new culture media product range specifically designed for cleanroom and isolator use. This advanced formulation was co-developed by a bioMérieux international research and development team and designed specifically for environmental monitoring in aseptic manufacturing environments.
BioFire Defense, a bioMérieux Company, Receives Fast-Track Authorization of FilmArray® Ebola Test
27 October, 2014
BioFire Defense, LLC of Salt Lake City, UT announced today that it has received Emergency Use Authorization by the U.S. Food and Drug Administration (FDA) for its commercial FilmArray® Ebola test (BioThreat-E testTM).
Business Review for the Nine Months Ended September 30, 2014
22 October, 2014
bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for the nine months ended September 30, 2014.
bioMérieux's VITEK MS System Nominated for Prestigious 2014 U.S. Prix Galien Award
13 October, 2014
The First FDA-Cleared Diagnostic Instrument to Utilize MALDI-TOF Mass Spectrometry to Rapidly Identify Harmful Bacteria and Yeast Recognized by Galien Foundation for Innovation in Healthcare Science
bioMérieux Launches chromID® Salmonella Elite, the New Generation of Culture Media for Earlier Detection of Salmonella Strains in Clinical Fecal Samples
18 September, 2014
bioMérieux, a world leader in the field of in vitro diagnostics, is pleased to announce the launch of chromID® Salmonella Elite, a new selective chromogenic culture medium for the isolation and rapid identification of Salmonella in stool samples.
bioMérieux Joins with the Rory Staunton Foundation to Host the First National Forum on Sepsis
15 September, 2014
Event to be held Sept. 17 in Washington D.C. and will feature Sen. Charles E. Schumer (D-NY), Konrad Reinhart, MD, of the Global Sepsis Alliance, Dr. Carl Flatley of the Erin K. Flatley Foundation and Thomas Frieden, MD, Director of the CDC.